Research and Markets: Global Migraine Therapeutics Pipeline Review 2014

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/pkbbbp/migraine) has announced the addition of the “Migraine – Pipeline Review, H1 2014″ report to their offering.

This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Migraine
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

Companies Involved in Therapeutics Development (Partial List)

  • Bristol-Myers Squibb Company
  • Allergan, Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Questcor Pharmaceuticals, Inc.
  • BioDelivery Sciences International, Inc.
  • Nektar Therapeutics
  • Merck & Co., Inc.
  • TheraJect, Inc.
  • Biofrontera AG
  • Astellas Pharma Inc.
  • Dr. Reddy’s Laboratories Limited
  • Pfizer Inc.
  • Impax Laboratories, Inc.
  • Revance Therapeutics, Inc.
  • IntelGenx Corp.
  • NovaDel Pharma, Inc.
  • Paladin Labs Inc.
  • Transcept Pharmaceuticals, Inc.
  • Pozen, Inc.
  • D-Pharm Ltd.
  • Ache Laboratorios Farmaceuticos S/A
  • Alder Biopharmaceuticals Inc.
  • CoLucid Pharmaceuticals, Inc.
  • Charleston Laboratories, Inc.
  • Pantarhei Bioscience BV
  • Indus Biotech Private Limited
  • NeurAxon, Inc.
  • Noxxon Pharma AG
  • Monosol Rx, LLC

For more information visit http://www.researchandmarkets.com/research/pkbbbp/migraine

  • Personal Investing Ideas & Strategies
  • Health Care Industry
  • Migraine
Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Did you find this useful? More Info: JustNoHeadache.com

  • DON’T  LEAVE  EMPTY-HANDED !!!

    Download your FREE Report on Headache

    slide12t

    Just a sneak peek…

    • Guide to cluster headache
    • Why do you get a headache?
    • Headache and migraine pain relief through hypnotherapy
    • Can stress cause severe headache?
    • Caffeine: the culprit behind our migraines
    • Menopause and headaches
    • Sinusitis: how serious is it?
    Download It Completely FREE

    Just Insert Your Name and email

    We will also send you a Complimentary copy of our Headache Newsletter. Our newsletter subscription has the latest information on Headache and Migraine treatments.

    We respect your privacy. We will NEVER sell, rent or share your email address. That’s more than a policy, it’s our personal guarantee!

  • Now you can have the Latest News on Headache

    hedac02-220

    Worried about Headache and Migraine? You can have now information about the latest treatments and medical research. All this and more in our Headache Newsletter.slide11t

    Try it for four weeks. We will even send you FREE our bonus health e-book with your trial subscription.

    All for just ONE PENNY

    Get the latest information – don’t be left in the dark on your condition.

     CLICK HERE 

    Check our special offer: Subscribe to one newsletter, get another newsletter for FREE!